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Abstract 
Abstract 
Review on der(11)t(1;11)(q11-23;q14-25), with data 
on clinics, and the genes involved. 
Keywords 
chromosome 1; chromosome 11; hematologic 
malignancies; multiple myeloma; myelodysplastic 
syndrome; biphenotypic acute leukaemia; acute 
myeloid leukemia; acute lymphoblastic leukaemia. 
Identity 
The reciprocal t(1;11)(q21;q23) translocation fuses 
the KMT2A (MLL) gene to MLLT11 (AF1q) on 
chromosomal band 1q21 
Clinics and pathology 
Disease 
De novo or secondary acute myeloid leukemia 
(AML) and acute lymphoblastic leukaemia (ALL), 
biphenotypic acute leukaemia (BAL), 
myelodysplastic syndrome (MDS), multiple 
myeloma (MM) and lymphoid malignancies. 
Phenotype/cell stem origin 
13 patients were diagnosed with myeloid 
malignacies: AML 6 cases (Najfeld et al., 1978; 
Archimbaud et al., 1998; Harrison et al., 1998; Stark 
et al., 2004), MDS 5 cases (González et al., 1992; 
von Bergh et al., 2000; Lange et al 2010; Dambruoso 
et al., 2012; Harrison et al., 1998),  polycythemia 
vera 1 patient (Douet- Guilbert et al., 2008) and 
chronic myelomonocytic leukemia 1 case (Muroi et 
al., 1996).  
Among them, 4 cases were identified as secondary 
diseases (Muroi et al., 1996; Archimbaud et al., 
1998; Harrison et al., 1998). There were 6 patients 
with ALL (Kaneko et al., 1982; Mamaeva et al., 
1983; Lorenzana et al., 1991; Harrison et al., 1998; 
Betts et al., 2001; Wan et al., 2004), one of them was 
a secondary leukaemia (Harrison et al., 1998) and 
there were 3 biphenotypic leukaemias (Hayhashi et 
al., 1990; Forrest et al., 1998; Jarvis et al., 1999). 
Chronic lymphocytic leukemia was diagnosed in 2 
patients (Qian et al., 1999; Travella et al., 2013), one 
of them transformed to Non hodgkin's lymphoma 
(Qian et al., 1999). 5 additional cases were diagnosed 
with lymphoma (Tien et al., 1997; Jerkeman et al., 
1999; Le Baccon et al., 2001; Dave et al., 2002; 
Narayan et al., 2013). The remaining patients were 
(1 case each) multiple myeloma (Lim et al., 2013), 
plasma cell leukemia (Avet-Loiseau et al., 2001), T-
prolymphocytic leukemia (Yamaguchi et al., 2003) 
and aggressive natural killer-cell leukemia (Ryder et 
al., 2007).  
Epidemiology 
There was 22 male and 11 female patients (sex ratio 
2:1). The most notable prevalence of male patients 
was in myeloid cases (10 males/3 females), while 
there were 6 male patients and 3 females with ALL. 
Most of the cases were adults with a median age of 
44 years (range 8-84 years) for all patients. The 
median age in myeloid cases was 42.8 years (range 
18 to 65 years) and 51.5 years in other neoplasms 
(range 36 to 70 years). The lowest median age was 
in ALL/biphenotypic leukemia patients (28.1 years, 
range 4 to 62 years) and the highest in lymphoma 
patients (67.2 years, range 37 to 84 years). 
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2 M  RARS  46,XY,der(11)t(1;11)(q12;q23) 
3 M/19 s-CMMoL 46,XY,der(11)t(1;11)(q21;q14)  
4 M  s-AML  
75,XXYY,-2,-3,+4,-10,der(11)t(1;11)(q21;q23)x2,-12,-14,-14,-15,-15,-16,-
17,i(17)(q10),+18, del(20)(q11)x2,10-25dmin  
5 M/18  s-MDS  47,XY,der(11)t(1;11)(q21;q23),+mar/48,idem,+mar  
6 F/48 s-AML 44,XX,-3,-5,-7,del(9)(p13),der(11)t(1;11)(q21;q23),-18,+2mar 
7 M/62 AML  
75,XXYY,,3n.,+1,+4,+4,+5,+6,+7,+8,+9,der(11)t(1;11)(q21;q23)x2,+13,-14,-5,i(17)(q10), 
+18,+18,+19,+20,del(20)(q12)x2,dmin 
8 M/22 AML- M5b 46,XX,der(11)t(1;11)(q31;q23)  
9 M/31 MDS s 46,XY,der(11)t(1;11)(q21;q23)/46,idem,add(6)(p21)  
10 F AML  
47,XX,+8,del(9)(q12q22),der(10)t(10;11)(p13;q23)/47,idem,der(11)t(1;11)(q23;q23)/ 
46,XX,der(7)t(3;7)(?;p22),t(9;10)(p22;p1? 5),der(11)t(10;11),-13,+22  
11 M/60  PV  s 46,XY,der(11)t(1;11)(q12;q14)/46,XY,del(20)(q12)  
12 M/65 RAEBI 47,XY,+8,der(11)t(1;11)(q21;q14-21)  






14 M/4 ALL 46,XY,der(11)t(1;11)(q21;q14)  
15 F/62 ALL 46,XX,der(11)t(1;11)(q21;q23) 
16 M BP-ALL  51,XY,+6,+der(11)t(1;11)(q21;q23),+19, +21,+22  
17 F/8 ALL  46,XX,add(4)(q35),t(9;11)(p22;q23),der(11)t(1;11)(q21;q14)  
18 M/21  BP-ALL  46,XY,der(11)t(1;11)(q21;q23) BMT A 84  
19 F/36 s- B-ALL 46,XX,der(11)t(1;11)(q21;q23),t(12;17)(p13;q21)  
20 M/16 BP-ALL 46,XY,der(6)t(1;6)(q23;p21)/46,XY,der(11)t(1;11)(q23;q21)  
21 M  ALL  
63,XXY,-1,-2,-3,-7,-9,+10,der(11)t(1;11)(q12;q22),-13,-15,+18,-19,-20,+21/61-
66,idem,+2  









23 M/70  PCL  
45,XY,der(5;20)(p10;p10),der(11)t(1;11)(q12;q23),t(11;14)(q13;q32),-13,der(20)t(5;20) 
(q10;p10)dup(5)  
24 M/60 T-PLL  
42,XY,add(1)(q21),add(7)(q22),i(8)(q10),-9,der(11)t(1;11)(q21;q23),del(12) (p12),-13,-14, -
15,add(17)(p13),add(18)(q23),-22,+mar/42,idem,+8,+15, add(21)(p11)/47,XY,+21  
25 M/36 ANKL 48,XY,+3,der(11)t(1;11)(q21;q25),add(22)(q13),+mar/50,idem,+13,+20  
26 F MM 
55-57,XX,+X,-X,der(X;14)(q10;q10),der(1)del(1)(q21q32)inv(1)(q13q32),+3,+5,+6,+7,-8, 
+9,+11,der(11)t(1;11)(q12;q25),+add(12)(p11),+13,+15,+18, +18,+19, +19,+21,+22,+1-2mar  

























18,+20,+21,-22,+3mar/49,idem,+i(6)(p10),+del(7)(q31q36) LN  
29 F/78  
DLB
CL  
43,XX,-1,?dup(3)(q21q27),der(11)t(1;11)(q23;q13),der(14)t(11;14)(q13;q32),-21 LN  





31 M/84 FL  48,XY,+X,der(11)t(1;11)(q12;q24),t(14;18)(q32;q21),+der(18)t(14;18)LN 




er(15)t(2;15)(p23;q13),der(16)t(7;16)(q22;q22), der(22)t(2;22)(q33;p11) LN 





Table 1.  Reported patients with der(11)(q11-q23;q14-25) in hematologic malignancies 
Abbreviations: M, Male; F, Female; AML, Acute myeloid leukemia; RARS,  Refractory anemia with ringed sideroblasts; CMMoL, 
Chronic myelomonocytic  leukemia; s-, secondary; MDS, myelodysplastic syndrome; PV, polycythemia vera;  RAEBI, Refractory 
anemia with excess blasts-1; ALL, acute lymphoblastic  leukemia; BP, Bilineage or biphenotypic leukemia; CLL, Chronic 
lymphocytic  leukemia; PCL, Plasma cell leukemia; T-PLL, T-prolymphocytic leukemia;  ANKL, Aggressive natural killer-cell  
leukemia; MM, Multiple myeloma; ENK/T, Extranodal NK/T-cell, NHL, Non-Hodgkin's  lymphoma; DLBCL, Diffuse large B-cell 
lymphoma; FL, Follicular lymphoma; LN,  lymph node. 1. Najfeld et al., 1978; 2. Gonz ález et al., 1992., 3. Muroi et al., 1996; 4. 
Archimbaud et al., 1998; 5-8,19. Harrison et al., 1998; 9. von Bergh et al., 2000; 10. Stark et al., 2004; 11. Douet- Guilbert et al., 
2008; 12. Lange et al 2010; 13. Dambruoso et al., 2012; 14. Kaneko et al., 1982; 15. Mamaeva et al., 1983; 16. Hayhashi et al., 
1990; 17. Lorenzana et al., 1991; 18. Forrest et al., 1998; 19. Harrison et al., 1998; 20. Jarvis et al., 1999; 21. Betts et al., 2001; 
22. Wan et al., 2004; 23. Avet-Loiseau et al., 2001; 24. Yamaguchi et al., 2003; 25. Ryder et al., 2007; 26. Lim et al., 2013; 27. 
Travella et al., 2013; 28. Tien et al., 1997; 29. Jerkeman et al., 1999; 30. Qian et al., 1999; 31. Le Baccon et al., 2001; 32. Dave 
et al., 2002; 33. Narayan et al., 2013. 
 
Prognosis 
Heterogeneous group of diseases; prognosis may 
depend on chronic versus advanced disease. One 
patient with BP-ALL was alive 84 months after bone 
marrow transplant (BMT) (Forrest et al., 1998), 
however 3 additional ALL patients (Mamaeva et al., 
1983; Martineu et al., 1996; Harrison et al., 1998) as 
well the 3 myeloid cases have relapsed and died of 
the disease with extremely short survival, including 
the sMDS case with BMT who died after 
transformation to AML (Harrison et al., 1998).  
Therefore, the prognosis is likely unfavorable in 




Unbalanced rearrangement, presents as 2 normal 
chromosomes 1, one normal chromosome 11 and a 
der(11)t(1;11) chromosome.  
Most patients presented with 1q21 (17 patients) and 
11q23 breakpoints (15 patients), while the 
der(11)t(1;11)(q21;q23) was the most frequent 
rearrangement (11 out of 33 patients). 
Additional anomalies 
Seven reported cases showed this translocation  
 
either as the sole abnormality (Najfeld et al., 1978; 
Kaneko et al., 1982; Mamaeva et al., 1983; González 
et al., 1992., Muroi et al., 1996; Forrest et al., 1998; 
Harrison et al., 1998; von Bergh et al., 2000) or as 
part of a simple karyotype in three cases (Harrison et 
al., 1998; von Berg et al., 2000; Lange et al 2010). In 
2 patients, it was found in a sideline clone (Jarvis et 
al., 1999; Douet- Guilbert et al., 2008). 
SIn myeloid malignancies, a trisomy 8 was found in 
4 cases (Najfeld et al., 1978; Harrison et al., 1998;  
Stark et al., 2004; Lange et al 2010), del(20q) in 4 
patients (Archimbaud et al., 1998; Harrison et al., 
1998; Douet- Guilbert et al., 2008; Dambruoso et al., 
2012)  and i(17)(q10) in 2 patients, both with near-
triploid karyotypes (Archimbaud et al., 1998; 
Harrison et al., 1998).  
The t(9;22)(q34;q11) was found as an accompanying 
anomaly in one ALL case. A complex karyotype was 
present in all lymphoma patients, while the 14q32 
rearrangement was found as an accompanying 
anomaly in 4 out of 6 lymphoma patients (Jerkmen 
et al., 1999; Qian et al., 1999; Le Baccon et al., 2001; 
Narayan et al., 2013). 
Variants 
To include: Addition patients with alternative 1q and 
11q breakpoints are included in Table 2.  
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46,XY,der(11)t(1;11)(q11-12;q25), 50,XX,+6,+8,+9,der(11),+18,+del(19)(p?),+20,+mar  






4 M  s-AML  
75,XXYY,-2,-3,+4,-10,der(11)t(1;11)(q21;q23)x2,-12,-14,-14,-15,-15,-16,-
17,i(17)(q10),+18, del(20)(q11)x2,10-25dmin  
5 M/18  s-MDS  47,XY,der(11)t(1;11)(q21;q23),+mar/48,idem,+mar  
6 F/48 s-AML 44,XX,-3,-5,-7,del(9)(p13),der(11)t(1;11)(q21;q23),-18,+2mar 







9 M/31 MDS s 46,XY,der(11)t(1;11)(q21;q23)/46,idem,add(6)(p21)  
10 F AML  
47,XX,+8,del(9)(q12q22),der(10)t(10;11)(p13;q23)/47,idem,der(11)t(1;11)(q23;q23)/ 
46,XX,der(7)t(3;7)(?;p22),t(9;10)(p22;p1? 5),der(11)t(10;11),-13,+22  
11 M/60  PV  s 46,XY,der(11)t(1;11)(q12;q14)/46,XY,del(20)(q12)  
12 M/65 RAEBI 47,XY,+8,der(11)t(1;11)(q21;q14-21)  






14 M/4 ALL 46,XY,der(11)t(1;11)(q21;q14)  





17 F/8 ALL  46,XX,add(4)(q35),t(9;11)(p22;q23),der(11)t(1;11)(q21;q14)  












21 M  ALL  63,XXY,-1,-2,-3,-7,-9,+10,der(11)t(1;11)(q12;q22),-13,-15,+18,-19,-20,+21/61-66,idem,+2  









23 M/70  PCL  
45,XY,der(5;20)(p10;p10),der(11)t(1;11)(q12;q23),t(11;14)(q13;q32),-
13,der(20)t(5;20)(q10;p10)dup(5)  
24 M/60 T-PLL  
42,XY,add(1)(q21),add(7)(q22),i(8)(q10),-9,der(11)t(1;11)(q21;q23),del(12)(p12),-13,-14, 
-15,add(17)(p13),add(18)(q23),-22,+mar/42,idem,+8,+15,add(21)(p11)/47,XY,+21  
25 M/36 ANKL 48,XY,+3,der(11)t(1;11)(q21;q25),add(22)(q13),+mar/50,idem,+13,+20  
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27 M/40 CLL 
46,XY,del(6)(q13q21),del(7)(q22q34),-8,add(9)(q34),del(9)(q22),der(11)t(1;11)(q21;q23),-
17,+r,dmin  
  Lymphomas   




der(11)t(1;11)q11;q25),-18, +20,+21,-22,+3mar/49,idem,+i(6)(p10),+del(7)(q31q36) LN  
29 F/78  DLBCL  43,XX,-1,?dup(3)(q21q27),der(11)t(1;11)(q23;q13),der(14)t(11;14)(q13;q32),-21LN  





31 M/84 FL  48,XY,+X,der(11)t(1;11)(q12;q24),t(14;18)(q32;q21),+der(18)t(14;18)LN 
32 F  DLBCL  
50,XX,+X,der(2)t(2;15)(p13;q13),der(11)t(1;11)(q21;q25),+12,+del(13)(q14),der(14)t(14;1
5)(q32;q22), der(15)t(2;15)(p23;q13),der(16)t(7;16)(q22;q22),der(22)t(2;22)(q33;p11) LN 
33 M/70  DLBCL 
47,XY,del(3)(q22q25),t(4;9)(q21;q34),del(6)(q16q23),del(9)(q34),der(11)t(1;11)(q21;q13),













35 M/46 lymph  HD  
75,XX,-Y,+2,+3,+4,der(4)t(1;4)(q12;q31)x2,+i(5)(q10),-6,-6,+add(7)(p15)x2,-8,+9,-
10,der(10)t(10;11) (p15;q13),i(10)(q10),+11,der(11) t(1;11)(q21q32;q13)x2,+14,-15,-17,-
17,-18,+19,+20,21,i(21)(q10)x2, +hsr(?),+5mar LN 
































20,der(20)t(1;20)(p11;q13),-21, +mar/ 80,idemx2  
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45  M/58 BL  
48,XY,inv(1),t(3;14;18),t(8;22)(q24;q11),add(9),der(11)t(1;11)(q25;q13),+18,+20 LN 
47,XY,inv(1),t(3;14;18),t(8;22),add(9),der(11)t(1;11),add(13)(?q12),add(15)(p12),+18 
46 M41 BL  46,XY,del(1)(q32),t(8;14)(q24;q32),der(11)t(1;11)(q32;q2?3),dup(13)(q2?q?) 
 
Table2. Abbreviations:  M, Male; F, Female; AML, Acute myeloid leukemia; RARS, Refractory anemia with ringed sideroblasts; 
CMMoL, Chronic myelomonocytic leukemia; s-, secondary; MDS, myelodysplastic syndrome; PV, polycythemia vera; RAEBI, 
Refractory anemia with excess blasts-1; ALL, acute lymphoblastic leukemia; BP, Bilineage or biphenotypic leukemia; CLL, 
Chronic lymphocytic leukemia; PCL, Plasma cell leukemia; T-PLL, T-prolymphocytic leukemia;  ANKL, Aggressive natural killer-
cell leukemia; MM, Multiple myeloma; ENK/T, Extranodal NK/T-cell, NHL, Non-Hodgkin's lymphoma; DLBCL, Diffuse large B-cell 
lymphoma; FL, Follicular lymphoma; LN, lymph node. HD., Hodgkin disease; FA., Fanconi anemia.  
1. Najfeld et al., 1978; 2. González et al., 1992., 3. Muroi et al., 1996; 4. Archimbaud et al., 1998; 5-8,19. Harrison et al., 1998;  
9. von Bergh et al., 2000; 10. Stark et al., 2004; 11. Douet- Guilbert et al., 2008; 12. Lange et al 2010; 13. Dambruoso et al., 
2012; 14. Kaneko et al., 1982; 15. Mamaeva et al., 1983; 16. Hayhashi et al., 1990; 17. Lorenzana et al., 1991; 18. Forrest et al., 
1998; 19. Harrison et al., 1998; 20. Jarvis et al., 1999; 21. Betts et al., 2001; 22. Wan et al., 2004; 23. Avet-Loiseau et al., 2001; 
24. Yamaguchi et al., 2003; 25. Ryder et al., 2007; 26. Lim et al., 2013; 27. Travella et al., 2013; 28. Tien et al., 1997; 29. 
Jerkeman et al., 1999; 30. Qian et al., 1999; 31. Le Baccon et al., 2001; 32. Dave et al., 2002; 33. Narayan et al., 2013. 34. 
Reeves et al., 1980; 35. Reeves et al., 1990; 36. Martineu et al., 1996; 37. Martin et al., 1996; 38. Brigaudeauet al., 1997; 39. 
Sawyer et al., 1998; 40. Alter et al., 2000;  41. Smadja et al., 2003;  42-43. Watanabe et al., 2003; 44. Einerson et al., 2005; 45. 
Li et al., 2006; 46. Havelange et al., 2013. 
 




Unbalanced translocations of the long arm of 
chromosome 1 to the long arm of chromosome 11 
are chromosomal abnormalities detectable in both 
hematologic neoplasms and lymphomas. Although 
cytogenetically heterogeneous, der(11)t(1;11)(q12-
21;q14-25) results in trisomy of genes located on 1q, 
associated with partial monosomy of 11q. May be 
found as a sole abnormality or part of a simple 
karyotype in myeloid malignancies and ALL, 
suggesting that it may be important for disease 
initiation in these malignancies. Whereas, in the 
majority of cases this unbalanced rearrangement was 
apparently a secondary aberration -occurring in 
complex karyotypes or together with the well-known 
primary abnormalities, therefore representing clonal 
evolution associated with disease progression. The 
possible role of previous mutagenic exposure in 
these cases, particularly in cases with secondary 
diseases remains a poorly understood finding. 
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